Press releases

Strategy, appointments, major clinical, medical and regulatory advances, and partnerships …: you can find all the latest Ipsen Group press releases arranged by year.

Filter by date
15 / 06 / 2017 - Paris (France)
Ipsen’s Partner Exelixis Announces Initiation of Phase 1b Trial of Cabozantinib in Combination with Atezolizumab in Patients with Locally Advanced or Metastatic Solid Tumors.
Download ( pdf - 183 kB)
01 / 03 / 2017 - Paris (France)
Ipsen’s Partner Lexicon Pharmaceuticals Announces That FDA Approves Lexicon Drug Xermelo™ (Telotristat ethyl) 250 mg as First and Only Oral Treatment for Carcinoid Syndrome Diarrhea in Cancer Patients with Metastatic Neuroendocrine Tumors.
Download ( pdf - 191 kB)
27 / 02 / 2017 - Paris (France)
Ipsen’s partner Exelixis announces clinical collaboration with Bristol Myers Squibb for late-stage combination trial in first-line renal cell carcinoma.
Download ( pdf - 179 kB)
23 / 07 / 2016 - Paris
Ipsen annonce l’autorisation par la FDA de Dysport® (abobotulinumtoxinA) injection dans le traitement de la spasticité des membres inférieurs chez l’enfant âgé de 2 ans et plus
17 / 12 / 2015 - Paris (France)
Ipsen announces its corporate agenda for 2016
17 12 2015 PR Ipsen financial agenda 2016 FINAL ( pdf - 31 kB)
01 / 12 / 2015 - Paris (France)
Ipsen’s partner Lexicon announced that Telotristat Etiprate had achieved positive top-line results in second phase 3 clinical trial
Telotristat etiprate obtient des premiers résultats positifs dans une deuxième étude clinique de phase 3 ( pdf - 58 kB)
19 / 11 / 2015 - Paris (France)
Ipsen and Interprotein enter into a research collaboration for novel peptides in endocrinology
2015 11 19 PR Ipsen Interprotein peptides Cushing endocrinology FINAL ( pdf - 55 kB)
29 / 10 / 2015 - Paris (France)
Ipsen: sales in the 3rd quarter and first nine months of 2015
2015 10 29 PR Q3 & 9-month sales FINAL ( pdf - 125 kB)
28 / 10 / 2015 - Paris (France)
Telesta Therapeutics and Ipsen announce exclusive license agreement for MCNA for the treatment of non-muscle invasive bladder cancer in major ex-United States territories
10-28-2015 PR Ipsen Telesta MCNA bladder FINAL ( pdf - 47 kB)
26 / 10 / 2015 - Paris (France)
Ipsen and EpiVax collaborate to produce next generation botulinum toxins
2015 10 26 Ipsen EpiVax next generation toxins ( pdf - 131 kB)
22 / 10 / 2015 - Paris (France)
Ipsen presents additional results from a Phase III clinical trial of the investigational use of Dysport® in children with spastic equinus foot deformity due to cerebral palsy
2015 10 PR Dysport final results phase III PLL FINAL ( pdf - 99 kB)
19 / 10 / 2015 - Paris (France)
Ipsen’s partner Lexicon announced at the 2015 Neuroendocrine Tumor Society Annual Symposium (Austin, Texas) that telotristat etiprate was associated with patient-reported improvements in social and physical function and emotional well-being according to new exit interview data from the Phase 3 TELESTAR study in cancer patients whose carcinoid syndrome was not adequately controlled by somatostatin analog (SSA) therapy.
Cancer Patients Treated with Lexicon’s Telotristat Etiprate Report Improved Function and Well-Being ( pdf - 60 kB)
01 / 10 / 2015 - Paris (France)
Ipsen announces release of an additional batch of Increlex® in the U.S.
2015 10 01 PR Increlex resupply Corporate FINAL FINAL ( pdf - 74 kB)
01 / 10 / 2015 - Paris (France)
Stéphane Bessette is appointed Executive Vice President, Human Resources of Ipsen
2015 10 01 PR Stéphane Bessette EVP RH (FINAL FINAL) ( pdf - 72 kB)
29 / 09 / 2015 - Paris (France)
Ipsen’s partner Lexicon presents phase III TELESTAR study data at ECC 2015 (Vienna, Austria) showing that telotristat etiprate reduces the average number of daily bowel movements in patients with carcinoid syndrome not adequately controlled by somatostatin analogues.
Lexicon Telotristat Etiprate ( pdf - 60 kB)
31 / 08 / 2015 - Paris (France)
Ipsen announces publication in The Lancet Neurology of the results of the phase III randomized study (NCT01313299) showing efficacy and safety of Dysport® (abobotulinumtoxinA) in adult patients with upper limb spasticity (ULS)
2015 08 31 Lancet Neurology Dysport ULS EN (FINAL) ( pdf - 79 kB)
03 / 08 / 2015 - Paris (France)
Ipsen’s partner, Lexicon Pharmaceuticals, announces positive results from TELESTAR phase 3 study showing that telotristat etiprate is effective in the treatment of carcinoid syndrome caused by neuroendocrine tumors not adequately controlled by somatostatin analogs
2015 08 03 telotristat etiprate ph3 results EN ( pdf - 298 kB)
31 / 07 / 2015 - Paris (France)
Ipsen: 2015 half-year results
2015-07-31-PR-Q2-sales-H1-2015-results-FINAL2 ( pdf - 554 kB)
31 / 07 / 2015 - Paris (France)
Ipsen: 2015 half-year results and 2015 objectives
2015-07-31-PR-Q2-sales-H1-2015-results-FINAL2 ( pdf - 554 kB)
Presentation H1 results FINAL ( pdf - 407 kB)
16 / 07 / 2015 - Paris (France)
Ipsen announces FDA approval of Dysport® (abobotulinumtoxinA) for injection in the treatment of upper limb spasticity in adults in the United States
PR AUL Approval FINAL ( pdf - 102 kB)
02 / 07 / 2015 - Paris (France)
Ipsen provides an update on 2020 strategy and outlook at Investor Day
PR Strategy 2020 EN - FINAL FINAL ( pdf - 35 kB)
Investor Day 02-07-2015 Presentation Media ( pdf - 966 kB)
03 / 06 / 2015 - Paris (France)
Ipsen initiates a share buyback program Shares will be cancelled to compensate dilution resulting from its free share plans
PR Rachat d'actions EN ( pdf - 168 kB)
02 / 06 / 2015 - Paris (France)
Ipsen confirms its eligibility for PEA-PME
PR PEA PME ( pdf - 92 kB)
29 / 05 / 2015 - Paris (France)
Combined Shareholders’ Meeting of IPSEN S.A. held on 27 May 2015
Communiqué Post-AG 2015 VA ( pdf - 223 kB)
19 / 05 / 2015 - Paris (France)
Ipsen strengthens its presence in the oncology field with the acquisition of OctreoPharm Sciences, a company developing innovative radiopharmaceuticals for the diagnosis and treatment of neuroendocrine tumours
PR Ipsen Octreopharm EN - FINAL ( pdf - 80 kB)
29 / 04 / 2015 - Paris (France)
Ipsen reports strong sales growth in Q1 2015 and raises guidance for the year
PR Q1 15 sales FINAL LAST 2 ( pdf - 81 kB)
16 / 04 / 2015 - Paris (France)
Active Biotech and Ipsen announce their decision to discontinue the development of tasquinimod in prostate cancer
16042015 Ipsen Active Biotech discontinuatio 10Tasq10 FINAL ( pdf - 64 kB)
08 / 04 / 2015 - Paris (France)
Ipsen and Hannover Medical School start joint research in recombinant botulinum neurotoxins for targeted secretion inhibitors
08 04 2015 Ipsen Hannover Medical School PR FINAL ( pdf - 239 kB)
01 / 04 / 2015 - Paris (France)
Ipsen inaugurates new Cambridge, MA R&D center, at the heart of the most important biomedical research & innovation hub in the USA, to expand U.S. presence
PR 01 04 2015 Cambridge Grand opening and Connecting with creativity EN ( pdf - 72 kB)
09 03 2015 IPSEN_Abstract_book-00 ( pdf - 1 MB)
01 / 04 / 2015 - Paris (France)
Ipsen expands ties to Harvard University with signing of a new Research Alliance Agreement
01 04 2015 PR Harvard Ipsen 2015 Research Alliance Agreement ( pdf - 57 kB)
31 / 03 / 2015 - Paris (France)
The Ipsen Group publishes its 2014 Registration document
PR DDR ( pdf - 112 kB)
04 / 03 / 2015 -
Precisions concerning the resupply of Increlex® in the U.S.
Precisions Increlex resupply 150304 ( pdf - 143 kB)
03 / 03 / 2015 - Paris (France)
Ipsen’s 2014 results and 2015 financial objectives
PR FY2014 results -FINAL ( pdf - 264 kB)
02 / 03 / 2015 - Paris (France)
Dominique Laymand is appointed as Ipsen’s Senior Vice President, Chief Ethics and Compliance Officer
PR appointment Dominique Laymand FINAL ( pdf - 222 kB)
02 / 03 / 2015 - Paris (France)
Ipsen Announces Third Resupply of Increlex® (mecasermin [rDNA origin] Injection) in the U.S. in 2015
PR Increlex resupply 3rd batch US FINAL ( pdf - 113 kB)
24 / 02 / 2015 - Paris (France)
Ipsen enters into option agreement to acquire Canbex Therapeutics
24 02 2015 PR Canbex Ipsen Multiple sclerosis- Final FINAL ( pdf - 61 kB)
03 / 02 / 2015 - Paris (France)
Ipsen: sales in the fourth quarter and full year 2014
PR FY14 sales FINAL ( pdf - 198 kB)
26 / 01 / 2015 - Paris (France)
Ipsen announces topline results of two double-blind phase III studies of Dysport® in lower limb spasticity in children and in adults
26012015 PR Dysport ALL & PLL ( pdf - 239 kB)
07 / 01 / 2015 - Paris (France)
Ipsen announces its corporate agenda for 2015
Ipsen - 2015 financial agenda ( pdf - 25 kB)
16 / 12 / 2014 - Paris (France)
François Garnier appointed Executive Vice President, General Counsel of Ipsen
12 2014 PR François Garnier_Nathalie Joannes General counsel EN ( pdf - 43 kB)
16 / 12 / 2014 - Paris (France)
Ipsen’s Somatuline® Depot® is the first therapy approved by the FDA in the United States for the treatment of patients with locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors
12 2014 corporate PR Approval Somatuline US FINAL ( pdf - 76 kB)
12 / 12 / 2014 - Paris (France)
Ipsen announces that the International Breast Cancer Study Group (IBCSG) presented phase 3 results evaluating the use of ovarian suppression to adjuvant treatment with tamoxifen
12 12 2014 - PR IBCSG Decapeptyl Breast cancer EN FINAL ( pdf - 54 kB)
28 / 11 / 2014 - Paris (France)
Ipsen announces FDA acceptance of filing for Dysport® in the treatment of upper limb spasticity in adult patients
28 11 2014 PR Dysport AUL sBLA FINAL ( pdf - 47 kB)
20 / 11 / 2014 - Paris (France)
Ipsen and CNRS create the “Archi-Pex” joint research and innovation lab, in collaboration with the University of Rennes 1 and CEA
RK rev 20 11 2014 PR Ipsen CNRS joint lab ARCHIPEX FINAL ( pdf - 343 kB)
18 / 11 / 2014 - Paris (France)
Ipsen and the Salk Institute renew their agreement for discovery research in medical sciences
18 11 2014 PR Ipsen Salk Insitute renewal agreement (FINAL) ( pdf - 298 kB)
06 / 11 / 2014 - Paris (France)
Otonomy obtains rights to gacyclidine data from Ipsen to support development of OTO-311 as a treatment for tinnitus
06 11 2014 Press release Otonomy and Ipsen gacyclidine EN ( pdf - 82 kB)
29 / 10 / 2014 - Paris (France)
Ipsen: sales in the 3rd quarter and first nine months of 2014
29 10 2014 PR First 9 months 2014 sales ( pdf - 201 kB)
22 / 10 / 2014 - Paris (France)
Lexicon and Ipsen enter into ex-North America/Japan licensing and commercialization agreement for telotristat etiprate
22 10 2014 PR Ipsen Lexicon telotristat etiprate carcinoid syndrom EN ( pdf - 71 kB)
10 / 10 / 2014 - Paris (France)
Aymeric Le Chatelier joins Ipsen as Executive Vice President, Chief Financial Officer
10 10 2014 PR appointment Aymeric Le Chatelier CFO (FINAL) ( pdf - 42 kB)
10 / 10 / 2014 - Paris (France)
Ipsen announces positive results from phase III clinical study of Decapeptyl® (triptorelin pamoate) 11.25 mg administered by subcutaneous route to prostate cancer patients
10 10 2014 PR Decapeptyl subcutaneous administration prostate cancer FINAL ( pdf - 51 kB)
02 / 10 / 2014 - Paris (France)
Susheel Surpal steps down as Executive Vice President, Chief Financial Officer of Ipsen to pursue other opportunities
2014 10 02 PR departure Susheel Surpal FINAL FINAL ( pdf - 38 kB)
27 / 09 / 2014 - Paris (France)
Ipsen presents preliminary results of exploratory proof-of-concept study with tasquinimod in four advanced tumor types at the ESMO 2014 Congress
PR 27092014 TASQ phase II umbrella Final ( pdf - 93 kB)
01 / 09 / 2014 - Paris (France)
Ipsen announces acceptance of filings for Somatuline® in the treatment of GEP-NETs in the US with priority review and in Europe
2014 09 01 PR acceptance filing Somatuline GEP NET US EU EN ( pdf - 116 kB)
29 / 08 / 2014 - Paris (France)
Ipsen: 2014 half-year results and 2014 objectives
PR H1 2014 FINAL ( pdf - 791 kB)
Télécharger la présentation ( pdf - 439 kB)
27 / 08 / 2014 - Basking Ridge (USA)
Ipsen North America Announces Second Resupply of Increlex® (mecasermin [rDNA origin] Injection) in the U.S. in 2014
Télécharger ( pdf - 238 kB)
17 / 07 / 2014 - Paris (France)
New England Journal of Medicine publishes Ipsen’s Somatuline® CLARINET® Phase III results in patients with metastatic gastroenteropancreatic neuroendocrine tumors
Download ( pdf - 81 kB)
11 / 07 / 2014 - Paris (France)
Ipsen and Galderma become exclusive partners for development and marketing of neurotoxins in the US, Canada, Brazil and Europe
PR Ipsen - Galderma FINAL ( pdf - 300 kB)
01 / 07 / 2014 - Paris (France)
Ipsen submits marketing authorization applications in the US and Europe for Somatuline® (lanreotide) in the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs)
PR filing Somatuline GEP NET US EU FINAL ( pdf - 94 kB)
04 / 06 / 2014 - Paris (France)
Ordinary Shareholders’ Meeting of IPSEN S.A. held on 4 June 2014
04 06 2014 PR general shareholders meeting 2014 EN ( pdf - 41 kB)
13 / 05 / 2014 - Paris (France)
Ipsen announces a step forward in the resupply of Increlex® in the U.S.
13 05 2014 PR Increlex resupply US FINAL ( pdf - 66 kB)
30 / 04 / 2014 - Paris (France)
Ipsen’s first quarter 2014 sales
30042014 PR Q1 2014 sales FINAL ( pdf - 184 kB)
12 / 04 / 2014 - Paris (France)
Ipsen announces a first set of results on positive phase III clinical study of Dysport® in the treatment of adults suffering from Upper Limb Spasticity at the 8th World Congress for NeuroRehabilitation in Istanbul
12042014 PR Dysport AUL WCNR EN FINAL EN ( pdf - 101 kB)
11 / 04 / 2014 - Paris (France)
The Fondation Ipsen celebrates its 30th anniversary with a prestigious conference on the perspectives of cancer research, “Biology viewed through the prism of cancer”, attended by 8 Nobel Prize laureates and the greatest scientists in biomedical research
PR 30th anniversary Fondation Ipsen EN ( pdf - 41 kB)
09 / 04 / 2014 - Paris (France)
Ipsen eligible for PEA-PME and included in CAC® PME index by Euronext
Download ( pdf - 32 kB)
20 / 03 / 2014 - Paris (France)
Ipsen announces that its controlling shareholder, Mayroy, sold approximately 7% of Ipsen’s share capital via private placement
PR Mayroy shareholding Ipsen EN FINAL ( pdf - 169 kB)
18 / 03 / 2014 - Paris (France)
Ipsen announces positive results from phase IIa clinical study of Dysport® in the treatment of patients with Neurogenic Detrusor Overactivity (NDO)
PR DYSPORT NDO - Phase IIa ( pdf - 51 kB)
28 / 02 / 2014 - Paris (France)
Ipsen’s 2013 results and 2014 financial objectives
28 02 2014 PR FY2013 Results_EN ( pdf - 249 kB)
2013 Annual Results Presentation ( pdf - 402 kB)
07 / 02 / 2014 - Paris (France)
Ipsen announces positive top line results from phase III clinical study of Decapeptyl® (triptorelin pamoate) 11.25 mg administered subcutaneously in patients with prostate cancer
PR Decapeptyl results 3M subcutaneous administation ( pdf - 316 kB)
05 / 02 / 2014 - Paris (France)
Ipsen announces clinical results of Dysport® Next Generation (DNG) and its intent to file the first ready-to-use liquid toxin A in Europe and ROW
05 02 2014 PR Dysport Next Generation EN ( pdf - 56 kB)
28 / 01 / 2014 - Paris (France)
Ipsen: sales in the fourth quarter and full year 2013
PR FY13 sales ( pdf - 502 kB)
22 / 01 / 2014 - Paris (France)
Ipsen implements a new governance in the United States to prepare for the launch of Somatuline® in oncology
PR New Governance US ( pdf - 35 kB)
17 / 01 / 2014 - Paris (France)
Ipsen announces at ASCO GI that ELECT® clinical trial of Somatuline® in the control of symptoms in GEP-NET 1 patients with carcinoid syndrome met its primary endpoint
17012014_PR_ELECT_results_ASCO_GI_EN ( pdf - 132 kB)
14 / 01 / 2014 - Paris (France)
Ipsen to set up its own US oncology team for Somatuline® Depot® (lanreotide) Injection in neuroendocrine tumors
14 01 2014 PR NET US ( pdf - 66 kB)
14 / 01 / 2014 - London (UK) and Paris (France)
Ipsen and GW Pharmaceuticals plc enter into agreement for Ipsen to promote and distribute Sativex® in Latin America
14012014 PR Ipsen GW Pharmaceuticals Sativex Latin America EN ( pdf - 77 kB)
10 / 01 / 2014 - Paris (France)
Jonathan Barnsley joins Ipsen as Executive Vice President, Technical operations
10 01 2014 PR appointment Jonathan Barnsley EN ( pdf - 55 kB)
23 / 12 / 2013 - Paris (France)
Ipsen announces its corporate agenda for 2014
23 12 2013 PF Corporate agenda 2014 EN ( pdf - 50 kB)
18 / 12 / 2013 - Paris (France)
Ipsen prepares for the resupply of Increlex® in Europe
18122013-PR-Increlex-resupply-EU_EN ( pdf - 64 kB)
18 / 12 / 2013 - Paris (France)
Ipsen and Mayoly Spindler enter into cross- promotion agreement for primary care activities in France
18 12 2013 PR Ipsen-Mayoly-Spindler-France ( pdf - 94 kB)
17 / 12 / 2013 - Paris (France)
Ipsen announces positive initial results from the international double-blind clinical phase III study of Dysport ® in the treatment of Adults suffering from Upper Limb Spasticity
17122013 PR Dysport AUL spasticity EN ( pdf - 75 kB)
12 / 12 / 2013 - Paris (France)
Dominique Brard joins Ipsen as Executive Vice President, Human Resources
2013 12 12 PR Dominique Brard ( pdf - 42 kB)
03 / 12 / 2013 - Paris (France)
The 13th Colloque Médecine et Recherche of the Fondation Ipsen in the Endocrinology series: “Brain Crosstalk in Puberty and Adolescence”
PR Brain crosstalk in puberty and adolescence ENG ( pdf - 57 kB)
22 / 11 / 2013 - Paris (France)
The 22nd Jean-Louis Signoret Neuropsychology Prize of the Fondation Ipsen has been awarded to Jean Decety (University of Chicago, Chicago, USA)
PR Jean Louis Signoret Prize Jean Decety 2013 EN ( pdf - 32 kB)
06 / 11 / 2013 - Paris (France)
Ipsen initiates a share buy-back program to partially cover its restricted share plans
06 11 2013 PR Restricted share plans EN ( pdf - 41 kB)
30 / 10 / 2013 - Paris (France)
Ipsen: sales in the third quarter and first nine months of 2013
30 10 2013 PR Q3 2013 sales EN ( pdf - 436 kB)
17 / 10 / 2013 - Paris (France)
The 8th Cell Press / Days of Molecular Medicine Global Foundation / Fondation Ipsen meeting in the Exciting Biologies series: “Biology of boundaries”
Download ( pdf - 72 kB)
09 / 10 / 2013 - Lund (Sweden) and Paris (France)
Active Biotech receives tasquinimod milestone payment from Ipsen for 10TASQ10 study
2013 10 09 TASQ milestone PR ( pdf - 60 kB)
06 / 10 / 2013 - Tokyo (Japan), Paris (France)
PeptiDream and Ipsen expand the scope of their collaboration for discovery of peptide drugs to treat serious endocrinologic disease
PR-Ipsen-PeptiDream-Collab-Expansion-EN ( pdf - 114 kB)
02 / 10 / 2013 - Paris (France)
New organization project and composition of the Executive Committee to accelerate the implementation of Ipsen’s strategy
PR New organization_EN_2Oct2013 ( pdf - 70 kB)
28 / 09 / 2013 - Paris (France)
Ipsen announces that results from CLARINET® Phase III clinical trial presented at the 2013 European Cancer Congress showed the antiproliferative effect of Somatuline® (lanreotide) 120 mg injection in the treatment of non-functioning gastroentero and pancreatic neuroendocrine tumors (“GEP-NETs”)
PR Results Clarinet ESMO ( pdf - 83 kB)
26 / 09 / 2013 - Paris (France)
Ipsen to relocate US R&D activities to Cambridge, MA in 2014
26 09 2013 PR Move to Cambridge EN ( pdf - 49 kB)
17 / 09 / 2013 - Paris (France)
Ipsen announces positive top line results from phase III ELECT® study of Somatuline® in the control of symptoms in NET patients with a history of carcinoid syndrome
PR ELECT primary endpoint EN ( pdf - 71 kB)
30 / 08 / 2013 - Paris (France)
Ipsen: 2013 half-year results and financial objectives
PR H1 2013 results EN ( pdf - 568 kB)
Results H1 2013 ( pdf - 250 kB)
30 / 08 / 2013 - Paris (France)
Detailed results of the phase III CLARINET study at the European Cancer Congress 2013 on 28 September 2013
PR Dates Late breaking news and Press conference Clarinet EN ( pdf - 42 kB)
15 / 07 / 2013 - Paris (France)
Ipsen strengthens its neurology R&D capabilities with the acquisition of Syntaxin, a leader in recombinant botulinum toxin technology
20130715-PR Syntaxin Ipsen EN ( pdf - 85 kB)
15 / 07 / 2013 - Paris (France)
Ipsen announce a sponsored research agreement with Harvard Medical School to discover novel engineered botulinum toxins for serious neurologic diseases
PR Harvard Ipsen ( pdf - 54 kB)